HOD HASHARON, February 3rd, 2021 – Nanorobotics Ltd., a preclinical-stage biopharmaceutical company dedicated to the development of molecular nanomachines (nanobots) for cancer therapeutics, today announced that two abstracts for the Company’s novel molecular nanomachines technology (MNMs) product platform were accepted for presentation at the American Association of Cancer Research (AACR) annual meeting being held virtually over two weeks, April 10-15 and May 17-21, 2021.
Accepted abstracts include preclinical data from in vitro and in vivo studies related to the Company’s selected indications (Non-Muscle Invasive Bladder Cancer) and Skin Cancer (melanoma, squamous and basal cell carcinoma). The results will demonstrate dramatic cancer eradication efficacy utilizing the Company’s platform technology.
- Light-activated molecular nanomachines kill bladder cancer cells
- Harnessing the mechanical power of nanomachines to treat cancer: Light-activated molecular nanomachines kill melanoma and oral cancer cells
All abstracts are scheduled to be available on the AACR website on April 10th, 2021.